Just the Beginning: What's Next for Radiotheranostics in Prostate Cancer?

preview_player
Показать описание
Geoffrey B. Johnson, MD, PhD, discusses 177Lu-PSMA-617 treatment for mCRPC along with other advances in theranostics.

Рекомендации по теме
Комментарии
Автор

When will this type of treatment be available for high risk Gleason 9?

sandraredmond
Автор

This is 2024 not 2022. How far have you gotten with your trials of Act-225?

woodrowdwightfrisbee